ClinicalTrials.gg
RecruitingNCT06121830Updated Nov 8, 2023

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)

A Phase 3 interventional study of DWP14012 20mg and DWP14012 40mg in Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease and Non-Erosive Esophageal Reflux Disease, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.

02

Conditions studied

  • Non-erosive Reflux Disease
  • Non-Erosive Gastro-Esophageal Reflux Disease
  • Non-Erosive Esophageal Reflux Disease

Keywords

  • NERD
03

In context

Non-Erosive Reflux Disease

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's planned enrollment of 324 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged 19 to 75 years, both inclusive, at the date of obtaining
  2. Subjects with no mucosal break(s) according to Los-Angeles grade on EGD performed at the same site within 2 weeks prior to Visit 1
  3. Subjects who have experienced heartburn for at least 12 weeks prior to Visit 1
  4. Subjects who have completed all symptom assessments (heartburn, acid regurgitation) in the subject diary from 7 days to 1 day prior to Visit 2
  5. Subjects who have experienced one of the following symptoms according to the symptom assessments in the subject diary from 7 days to 1 day prior to Visit 2
  6. Subjects who have reported at least moderate burning sensation in the esophagus (behind the breastbone) for heartburn symptoms for at least 4 days
  7. Subjects who have reported at least moderate pain in the esophagus (behind the breastbone) for heartburn symptoms for at least 4 days
  8. Subjects who are capable of understanding the provided information and able to comply with all the study procedures including filling out the subject diary and questionnaire throughout the study
  9. Subjects who voluntarily decide to participate in the study and sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have Barrett's esophagus, gastroesophageal varix, viral/fungal gastrointestinal infection, esophagostenosis, ulcer stenosis, active peptic ulcer, gastrointestinal bleeding, or a malignant tumor identified on EGD performed within 2 weeks prior to Visit 1
  2. Subjects who have warning symptoms of malignant gastrointestinal tract diseases such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or hematochezia at Visit 1 (However subjects who have additional warning symptoms besides typical symptoms of gastroesophageal reflux disease [GERD] may be included if the result of endoscopy, etc. is negative for the presence of tumor.)
  3. Subjects with Zollinger-Ellison syndrome at Visit 1
  4. Subjects with eosinophilic esophagitis at Visit 1
  5. Subjects who are diagnosed with erosive GERD, acute upper gastrointestinal bleeding, gastric ulcer, or duodenal ulcer within 8 weeks prior to Visit 1
  6. Subjects who are diagnosed with FD, FH, RH, primary esophageal motility disorder, IBS, and IBD within 12 weeks prior to Visit 1
  7. Subjects who had a surgery to reduce gastric acid secretion, or gastric or esophageal surgery (e.g., gastrectomy, mucosal resection, etc.) (Except, simple perforation surgery and endoscopic resection of benign tumors)
  8. Subjects who have a disease of hepatic, renal, neurologic, respiratory, endocrine, hemato-oncologic, cardiovascular or urinary system at Visit 1
  9. Subjects who have history of alcohol or other drug abuse within 1 year prior to Visit 1
  10. Subjects diagnosed with malignant tumor within 5 years prior to Visit 1 (Subjects completely healed for ≥5 years from the last treatment without recurrence are allowed to be enrolled.)

    • Subjects with cured basal cell carcinoma of the skin or carcinoma in situ of the cervix are allowed to be enrolled regardless of time period
    • Subjects with a history of digestive malignant tumor are excluded regardless of the time period
  11. Subjects who have or had bipolar disorder, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other clinically significant psychiatric disorders
  12. Subjects with scleroderma (systemic sclerosis) or systemic lupus erythematosus
  13. Subjects who have , or medical history of clinically significant hypersensitivity, to any components of the IP
  14. Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    DWP14012 20mg

    Once daily with water regardless of meals without chewing or crushing for 4 weeks.

    Drug: DWP14012 20mg

  • Experimental
    DWP14012 40mg

    Once daily with water regardless of meals without chewing or crushing for 4 weeks.

    Drug: DWP14012 40mg

  • Placebo comparator
    Placebo

    Once daily with water regardless of meals without chewing or crushing for 4 weeks.

    Drug: Placebo

Interventions

  • DWP14012 20mg, tablet, orally, once daily for up to 4 weeks

  • DWP14012 40mg, tablet, orally, once daily for up to 4 weeks

  • DrugPlacebo

    Placebo, tablet, orally, once daily for up to 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of heartburn-free days for 4 weeks (daytime/nighttime)

    Time frame: 4 Weeks

Secondary outcomes

  1. Percentage of major symptom-free (heartburn, acid regurgitation, or heartburn/acid regurgitation) days for 2 and 4 weeks (daytime/nighttime, daytime and nighttime)

    Time frame: 4 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Jan 2025, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Nov 8, 2023
StartActual
Aug 31, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Mar 2025
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06121830
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Aug 31, 2023
Primary completion
Jan 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Nov 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion